Early Gout Treatment Trial Data from the Netherlands

Comprising data from a pragmatic randomized controlled trial with 308 participants comparing Treat-to-Target and Treat-to-Avoid-Symptoms strategies for early gout. Participants were followed for 24 months across seven centers in the Netherlands. Data include baseline characteristics, laboratory measurements, medication use, gout flares, adverse events, and patient-reported outcomes collected every three months.

Use Cases

• Analyze gout flare frequency and severity over 24 months to compare treatment strategies.
• Model the relationship between serum urate levels and the occurrence of adverse events.
• Examine patient-reported outcome measures collected every three months for trends in symptom management.
• Investigate medication use patterns in relation to laboratory measurements like eGFR.

Strengths

• Data from a pragmatic randomized controlled trial with 308 participants.
• Longitudinal data with 24 months of follow-up and measurements collected every three months.
• Includes multiple data types: clinical lab results, medication records, adverse events, and patient-reported outcomes.

Limitations

• Sample size of 308 participants may limit statistical power for some subgroup analyses.
• Geographic focus on the Netherlands may limit generalizability to other populations.
• Access is subject to consent and approval by VieCuri Medical Center, which may delay or restrict use.

Provenance

Source

DataverseNL Harvested Dataverse, author Anusha Moses.

Collection Method

Data captured using Castor EDC from a pragmatic multicentre open-label randomized controlled trial.

Time Range

2021–2025, with 24-month participant follow-up.

Freshness

Data covers the period 2021–2025 and was last updated in February 2026.

Geography

Seven centers in the Netherlands.